Mary Beth Wire

1.2k total citations
36 papers, 957 citations indexed

About

Mary Beth Wire is a scholar working on Infectious Diseases, Virology and Hematology. According to data from OpenAlex, Mary Beth Wire has authored 36 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 14 papers in Virology and 12 papers in Hematology. Recurrent topics in Mary Beth Wire's work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (14 papers) and Platelet Disorders and Treatments (12 papers). Mary Beth Wire is often cited by papers focused on HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (14 papers) and Platelet Disorders and Treatments (12 papers). Mary Beth Wire collaborates with scholars based in United States, United Kingdom and Spain. Mary Beth Wire's co-authors include Mark Shelton, Bin Peng, Daphne Williams, Scott D. Studenberg, Yu Lou, Laurene H. Wang, Jung Wook Park, Carolyn J. Bowen, Richard Peck and Yin Yin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Mary Beth Wire

36 papers receiving 916 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Beth Wire United States	18	325	289	246	186	170	36	957
J Biollaz Switzerland	14	263 0.8×	157 0.5×	119 0.5×	114 0.6×	130 0.8×	16	769
Anne Hulin France	21	180 0.6×	224 0.8×	200 0.8×	168 0.9×	119 0.7×	74	1.4k
Rosa F. Yeh United States	12	348 1.1×	135 0.5×	73 0.3×	140 0.8×	166 1.0×	25	682
K. Tsuchiya Japan	23	805 2.5×	229 0.8×	140 0.6×	190 1.0×	523 3.1×	76	1.6k
Marie‐Claude Gagnieu France	19	278 0.9×	273 0.9×	43 0.2×	145 0.8×	71 0.4×	63	889
Lisa M. Almond United Kingdom	17	381 1.2×	129 0.4×	33 0.1×	324 1.7×	199 1.2×	34	1.1k
Olena Kis Canada	10	231 0.7×	50 0.2×	93 0.4×	212 1.1×	132 0.8×	15	541
Anther Keung United States	14	310 1.0×	193 0.7×	43 0.2×	384 2.1×	76 0.4×	24	948
Caroline Solas France	23	920 2.8×	258 0.9×	41 0.2×	208 1.1×	430 2.5×	94	1.5k
Eve‐Irene Lepist United States	16	324 1.0×	169 0.6×	20 0.1×	278 1.5×	125 0.7×	22	975

Countries citing papers authored by Mary Beth Wire

Since Specialization

Citations

This map shows the geographic impact of Mary Beth Wire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Beth Wire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Beth Wire more than expected).

Fields of papers citing papers by Mary Beth Wire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Beth Wire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Beth Wire. The network helps show where Mary Beth Wire may publish in the future.

Co-authorship network of co-authors of Mary Beth Wire

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Beth Wire. A scholar is included among the top collaborators of Mary Beth Wire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Beth Wire. Mary Beth Wire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wire, Mary Beth, et al.. (2022). Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants. SHILAP Revista de lepidopterología. 23(1). 1–8. 3 indexed citations

Wire, Mary Beth, et al.. (2017). Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects. Open Forum Infectious Diseases. 4(suppl_1). S311–S311. 8 indexed citations

Zhang, Jianping, et al.. (2014). Modeling and Simulation Support Eltrombopag Dosing in Thrombocytopenic Patients with Chronic HCV Infection. Pharmaceutical Research. 32(6). 2015–2028. 6 indexed citations

Wire, Mary Beth, Fang Lei, Azra Hussaini, Joseph F. Kleha, & Dickens Theodore. (2014). Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir. Antimicrobial Agents and Chemotherapy. 58(11). 6704–6709. 5 indexed citations

Fortuny, Clàudia, Dan Duiculescu, H Garges, et al.. (2013). Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children. The Pediatric Infectious Disease Journal. 33(1). 50–56. 8 indexed citations

Cotton, Mark F., Noris Pavía-Ruz, H Garges, et al.. (2013). Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data. The Pediatric Infectious Disease Journal. 33(1). 57–62. 6 indexed citations

Farrell, Colm, et al.. (2013). Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. British Journal of Clinical Pharmacology. 77(3). 532–544. 13 indexed citations

Wire, Mary Beth, et al.. (2012). A Randomized, Open-Label, 5-Period, Balanced Crossover Study to Evaluate the Relative Bioavailability of Eltrombopag Powder for Oral Suspension (PfOS) and Tablet Formulations and the Effect of a High-Calcium Meal on Eltrombopag Pharmacokinetics When Administered With or 2 Hours Before or After PfOS. Clinical Therapeutics. 34(3). 699–709. 34 indexed citations

Deng, Yanli, Mary Beth Wire, Carolyn J. Bowen, et al.. (2011). Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects. Drug Metabolism and Disposition. 39(9). 1734–1746. 38 indexed citations

10.

Allred, Alicia J., Carolyn J. Bowen, Jung Wook Park, et al.. (2011). Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. British Journal of Clinical Pharmacology. 72(2). 321–329. 63 indexed citations

11.

Ouellet, Danièle, et al.. (2010). Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing. The Journal of Clinical Pharmacology. 51(10). 1403–1417. 32 indexed citations

12.

Park, Jung Wook, Mary Beth Wire, Carolyn J. Bowen, et al.. (2010). Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(3). 301–308. 22 indexed citations

13.

Park, Jung Wook, Mary Beth Wire, Jianping Zhang, et al.. (2010). Eltrombopag does not affect cardiac repolarization: results from a definitive QT_c study in healthy subjects. British Journal of Clinical Pharmacology. 70(1). 24–33. 18 indexed citations

14.

Cohen, Calvin, Edwin DeJesus, Anthony LaMarca, et al.. (2010). Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial. HIV Clinical Trials. 11(5). 239–247. 3 indexed citations

15.

Pérez‐Elías, Maria Jesús, Enrique Ortega, José Hernández‐Quero, et al.. (2009). Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment. Antimicrobial Agents and Chemotherapy. 53(12). 5185–5196. 10 indexed citations

16.

Cao, Ying‐Jun, Patrick F. Smith, Mary Beth Wire, et al.. (2008). Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Fosamprenavir‐Ritonavir in Opioid‐Dependent Subjects. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(7). 863–874. 15 indexed citations

17.

Wire, Mary Beth, Mark Shelton, & Scott D. Studenberg. (2006). Fosamprenavir. Clinical Pharmacokinetics. 45(2). 137–168. 91 indexed citations

18.

Shelton, Mark, Susan L. Ford, Julie Borland, et al.. (2006). Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics. JAIDS Journal of Acquired Immune Deficiency Syndromes. 42(1). 61–67. 26 indexed citations

19.

Wire, Mary Beth, Charles H. Ballow, Sandra L. Preston, et al.. (2004). Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS. 18(6). 897–907. 29 indexed citations

20.

Hendrix, Craig W., Mary Beth Wire, Yu Lou, et al.. (2004). Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Amprenavir in Opioid‐Dependent Subjects. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(9). 1110–1121. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact